ArticleEndocrine, metabolic & immune disorders drug targets2026
Investigation of the Mechanism of Action of Liu Miao San in the Treatment of Lipid Metabolism Disorders on the basis of Network Analysis and Dynamic Ultrasound.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLipid metabolism disorders are a critical global health issue. Liu Miao San (LMS), a traditional Chinese medicine (TCM) formula, has demonstrated clinical efficacy against these disorders; however, its underlying mechanism remains unclear.
methodsNetwork analysis was performed to predict LMS targets using the TCMSP and ETCM databases, followed by protein-protein interaction (PPI) network construction and GO/KEGG enrichment analyses. These predictions were validated
resultsNetwork analysis identified SREBP1 and PPARγ as core targets. DISCUSSION: LMS ameliorates lipid metabolism disorders through a dual regulatory mechanism: suppressing SREBP1 (reducing fatty acid and cholesterol synthesis) and activating PPARγ (promoting cholesterol efflux and exerting anti-inflammatory effects). This multitarget action addresses both hepatic and systemic lipid dysregulation.
conclusionLMS exerts therapeutic effects via SREBP1/PPARγ modulation, supporting its clinical application in TCM and providing a methodological framework for mechanistic studies of complex herbal formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.